Why the study?
Carriers of the amyloidogenic p.V142I transthyretin variant show modest echocardiographic changes at average age 74 years, but late-life changes remain unknown.
Does the p.V142I transthyretin variant affect late-life echocardiographic parameters in Black individuals?
Does the p.V142I transthyretin variant affect late-life echocardiographic parameters in Black individuals?
This study evaluates the late-life echocardiographic progression in Black individuals carrying the amyloidogenic p.V142I transthyretin variant.
May inform variant-specific monitoring in Black individuals; leaves open need for prospective outcome studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: